Philadelphia, Pennsylvania – The majority of patients with metastatic colorectal cancer whose cancer did not progress during initial treatment with immune checkpoint inhibitors (ICIs) had no disease progression two years after discontinuing treatment. ICIs have proven effective against certain solid tumors, including those with a high microsatellite instability (MSI-H) or...
treatment News
Oslo – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug Designation to its lead product candidate, fimaporfin, for combination treatment with gemcitabine in patients with inoperable locally advanced or metastatic bile...
Oslo (Norway) – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that the first US patient has been enrolled into the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients. The RELEASE study...
FRANKFURT, Germany – The term ‘leukemia’ encompasses various forms of blood cancer, including acute myeloid leukemia (AML). In AML, blood cells in the early stages – the stem cells and the precursor cells that develop out of them – degenerate. AML is the second most common leukemia in children, accounting...
PHILADELPHIA, PA — Phenylketonuria (PKU) is a rare newborn genetic disease that impacts between 1 in 10,000 to 1 in 20,000 people, depending on the individuals’ genetic ancestry. PKU causes an amino acid—called phenylalanine (Phe)—to build up in the bloodstream. Uncontrolled PKU can lead to intellectual disability, psychiatric issues, and...
BOSTON, Mass. — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PGN-EDODM1, an investigational candidate...
IRVINE, Calif. — PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has reached...
New Delhi – Achalasia is a disease where the function of the oesophagus stops working overtime. It is thought to be neural degeneration of the selective nerve fibers in the body of the oesophagus and the valve at the top of the stomach. It is a rare disease with an...
TUSTIN, Calif. — Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today highlighted the progress that the company has achieved in its Phase II program assessing the combination of bavituximab and chemotherapy in three separate cancer trials. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body’s own immune system...
Peregrine has presented the data for ongoing trail for brain cancer at Society of Nuclear Medicine 2009 Annual Meeting. The study supports the potential for Cotara to treat brain cancer. Cotara, a targeted monoclonal antibody linked to a radioisotope, is being developed as a potential new treatment for glioblastoma multiforme...